Organigram faces significant headwinds as revenue growth contracted by 34.5% in 2026Q2, signaling potential market saturation in the Canadian recreational sector. While the company maintains a conservative debt-to-equity ratio of 0.02, the persistent disconnec...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 11, 2026 | $0.54+5520.0% vs -$0.01 | $74M+9.2% vs $68M |
Q2 2026 May 12, 2026 | -$0.01+5.4% vs -$0.01 | $43M-15.0% vs $51M |
Q1 2026 Feb 10, 2026 | $0.11+1163.0% vs -$0.01 | $46M-13.1% vs $53M |
Q4 2025 Dec 16, 2025 | -$0.20-1900.0% vs -$0.01 | $57M+9.6% vs $52M |
KORU Medical Systems (NASDAQ: KRMD - Get Free Report) and Organigram Global (NASDAQ: OGI - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk. Profitability This table compares KORU Medical
TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (the "Company" or "Organigram"), Canada's #1 cannabis company by market share and a growing global cannabis platform, today announced details of its 2026 OG Investor Session. “Since our last investor session, we've welcomed a new leadership team, completed our first full quarter with Sanity Group, and sharpened our strategy for the years ahead. We look forward to updating our stakeholders on how we're aligning Organigram.
Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (âOrganigramâ or the âCompanyâ) today announced an important milestone in its global growth strategy thr
TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (“Organigram” or the “Company”) today announced an important milestone in its global growth strategy through the accelerated integration of Sanity Group GmbH (“Sanity”) and the alignment of leadership, operations and market development activities across the combined organization. To support the combined organization, Organigram has appointed Finn Age Hänsel as President, Rest of World & Chief Strategy Officer, and Adr.
Benchmark OGI against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Organigram Global Inc. (OGI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.09 | $153.44M | -10.99 | 16.42% | -9.55% | -5.43% | — | |
| $0.94 | $394.99M | -1.50 | 5.8% | -80.67% | -32.79% | — | |
| $4.11 | $459.63M | -3.77 | -18.77% | -12.9% | -8.09% | — | |
| $4.22 | $261.4M | -2.78 | -6.61% | -38.15% | -20.36% | — | |
| $3.40 | $1.27B | -135.46 | 26.81% | 28.74% | 6.18% | — | |
| $1.40 | $364.42M | -32.92 | 2.82% | -2.34% | -1.99% | — |
Organigram Global Inc. (OGI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when OGI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Organigram Global Inc. (OGI) stock FAQ — growth, dividends, profitability & financials explained
Organigram Global Inc. (OGI) reported $309.1M in revenue for fiscal year 2025.
Organigram Global Inc. (OGI) grew revenue by 16.4% over the past year. This is strong growth.
Yes, Organigram Global Inc. (OGI) is profitable, generating $86.6M in net income for fiscal year 2025 (-9.6% net margin).
Organigram Global Inc. (OGI) has a return on equity (ROE) of -5.4%. Negative ROE indicates the company is unprofitable.
Organigram Global Inc. (OGI) had negative free cash flow of $29.7M in fiscal year 2025, likely due to heavy capital investments.
